Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 304

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 304
---
—— 647 — — 647 Unrealized loss on marketable securities—— —— —— —— —— — (8)— (8)Net loss—— —— —— —— —— — — (11,847)(11,847)Balance at March 31, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 3,102,869$3 $5,167 $(8)$(131,245)$(126,083)Exercise of common stock options————————31,715—38——38 Vesting of restricted common stock awards————————45,665————— Stock-based compensation expense——————————971——971 Unrealized loss on marketable securities———————————(148)—(148)Net loss————————————(8,552)(8,552)Balance at June 30, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 3,180,249$3 $6,176 $(156)$(139,797)$(133,774)

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-4

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share amounts) 

(Unaudited)

Series SeedSeries ASeries BSeries C Common Stock AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncomeAccumulatedDeficitTotalStockholders’Equity (Deficit)Preferred Stock Preferred StockPreferred Stock Preferred Stock SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 4,722,763$5 $17,000 $368 $(181,086)$(163,713)Conversion of convertible preferred stock to common stock upon closing of initial public offering(3,963,963)(13,014)(5,704,161)(25,235)(11